Loading data for EVMN — first visit, this takes a few seconds.

Evommune, Inc. (EVMN)

NYSE: EVMN · Real-Time Price · USD

12.48

+0.00 (0.00%)

At close: Sep 11, 2026, 3:59 PM

12.20

+1.67%

Pre-market: 5:25 AM

Alert

The price, the headline numbers and the latest news, in one place.

0.00% (1D)

Bid	0
Market Cap	436M
Revenue (ttm)	10M
Net Income (ttm)	-94.7M
	0.00
	-11.82
	n/a
	-3.53
P/B (ttm)	1.57
P/S (ttm)	43.55
Earnings Date	Nov 16, 2026

Ask	0
Volume	366,068
Avg. Volume (20D)	794,879
Open	12.50
Previous Close	12.48
Day's Range	12.33 - 12.78
52-Week Range	10.47 - 33.20
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About EVMN

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Nov 6, 2025

Employees 48

Stock Exchange NYSE

Ticker Symbol EVMN

Website https://www.evommune.com

Full Company Profile

Financial Performance

In 2025, Evommune's revenue was 13M, an increase of undefined% compared to the previous year's n/a. Earnings were -68.87M, an increase of undefined%.

Financial Statements

Earnings Surprise

Evommune has released their quarterly earnings on Aug 6, 2026:

Revenue of $0 misses estimates by $0, with NaN% YoY growth.
EPS of -0.89 misses estimates by -0.22, with -Infinity% YoY decline.

Next Earnings Release

Evommune, Inc. is scheduled to release its earnings on Nov 16, 2026, during market hours.
Analysts project revenue of ... Upgrade

Why Price Moved

News

2 months ago · Zacks

EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal

Evommune shares fall after its phase IIb CSU study misses the primary endpoint, prompting the company to halt further development of EVO756 for the indication.

2 months ago · Clinical Trials Arena

Evommune terminates oral drug’s development in CSU

While Evommune is terminating development of the oral drug in CSU, trials in AD and migraine prophylaxis will continue.

2 months ago · InvestorsHub

Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN)

Evommune, Inc. (NYSE:EVMN) shares dropped 17% on Monday after the company announced that its Phase 2b study of EVO756 in chronic spontaneous urticaria (CSU) failed to achieve its primary efficacy endp...